Catalent, Inc. CTLT
63.48 0.00 (+0.00%)
At closeDec 17, 2024, 4:00 PM EST
63.44 Day range 63.50
52-week range unavailable
- Market cap
- 11.52B
- Volume
- 13.67M
- Open
- 63.49
- Previous close
- 63.48
- Day's range
- 63.44 – 63.50
- Earnings date
- Nov 5, 2024
2Y +19.60 (+44.67%)
Next earnings
Nov 5, 2024
Expected Nov 5, 2024. Consensus EPS estimate 0.11.
Financials — quick view
CTLT Revenue — quarterly 1.02B
CTLT Net income — quarterly -129.00M
CTLT EPS — quarterly -0.71
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 5, 2024 | Sep 1, 2024 | 0.11 | — | — | — |
| Aug 29, 2024 | Jun 1, 2024 | 0.46 | — | — | — |
| May 8, 2024 | Mar 1, 2024 | 0.24 | — | — | — |
| Aug 29, 2023 | Jun 1, 2023 | 0.10 | — | — | — |
News
Catalent and Mantra™ Announce Commercial Supply Agreement for Single-Serve Oral Gel Portfolio 
Scholar Rock drops Catalent facility from marketing application for muscle weakness drug 
Taysha Gene Therapies and Catalent Expand Strategic Partnership to Include Future Commercial Manufacturing Support of TSHA-102 Gene Therapy for Rett Syndrome 
Catalent Launches Qai™ to Reimagine Quality Assurance for its Manufacturing Services 
Cartherics and Catalent Expand Commercial License Agreement 
Catalent and GelMEDIX Enter Global Partnership for the Development and Clinical Manufacturing of iPSC-Derived Cell Therapies in Ocular and Retinal Diseases 
SmartCella and Catalent Sign Nonexclusive License Agreement for GMP iPSCs 
Lisata Therapeutics Highlights Positive Preclinical Data of Certepetide as Part of Antibody-Drug Conjugate Combinations as Reported by Licensing Partner Catalent 
Catalent Debuts New Corporate Brand, Elevating Customer Service Excellence by “Championing the Missions that Matter™” 
Lisata Therapeutics CEO discusses Catalent deal - ICYMI
Your note
Sign in to keep a note on CTLT — it syncs with the Stock Master app.